Analytical Science

Streamlined workflows help scientists plot a course for painless peptide mapping

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Why does the full potential of biosimilars remain untapped? Four experts weigh in.

Could NIR CI offer improved monitoring of tablet manufacture?

There is a lack of attention given to racemization in drug discovery…

Ten thousand reactions per hour – or else? No problem!

We speak with four experts to gain a fresh perspective on biopharmaceutical characterization.

Big pharma, vulnerable supply chains, and an international religious network…

Why your efforts to introduce "PAT" may not be working as intended…

How a better understanding of raw materials has increased the potential for biopharmaceutical companies to understand their process variability.